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induced relaxation was not changed significantly. The contractile 
response to Phe significantly increased in arteries that were incubated 
with ET-1, compared with controls. In addition, PARP-1 and PARP 
expressions increased significantly in thoracic aorta rings incubated 
with ET-1. The diminished vasoreactivity in response to ACh and 
Phe as well as ET-1-related changes in expressions of PARP-1 and 
PAR were significantly improved by the concomitant incubation with 
either PEG-SOD plus apocynin, or PJ34.
Conclusion: The results of this study suggest that ET-1 causes a sig-
nificant alteration in vascular reactivity of thoracic artery, and this 
alteration seems to be via oxidative stress in thoracic artery endothe-
lium with subsequent DNA damage and activation of PARP pathway.
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Introduction: Improvement of left ventricular ejection fraction 
(LVEF) in patients with dilated cardiomyopathy (DCM) can be 
observed after a minimum of 6 months of therapy. Many factors 
contribute to the rate of improvement. We proposed to investigate the 
importance of certain clinical variables and treatment particularities 
on the prognostic of patients with DCM.
Patients (or Materials) and Methods: We included in our study 
patients selected retrospectively from the Clinical County Hospital 
database that had been admitted to the hospital between 2010 and 
2012 with the principal diagnosis of DCM, presented a reduced 
LVEF, and had a follow-up within minimum 6 months. We consid-
ered improvement an increase of > 20% the LVEF value at follow-up. 
We then separated our patients into 2 groups based on improvement 
or no improvement of LVEF. Clinical parameters were compared by 
univariable analysis. The purpose was to identify factors that were 
associated with improvement of LVEF.
Results: In the statistical model, sex, etiology of cardiomyopathy, 
disease duration, NYHA class, heart rate at rest, presence of co-
morbidities (high systolic blood pressure, diabetes), serum sodium 
levels, beta-blocker type, and adherence to treatment were signifi-
cantly associated with improvement of ejection fraction.
Conclusion: The variables observed as being associated with 
improvement of LVEF may be used to identify patients who will 
benefit from standard therapy and those who will need more aggres-
sive pharmacologic therapies or implantable devices.
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Introduction: This study was aimed to examine the effect of chronic 
taurine treatment on corpus cavernosum dysfunction in diabetic rats 
and to investigate possible underlying mechanisms.
Patients (or Materials) and Methods: Thirty male rats were ran-
domized to 3 groups of 10 each, including control, diabetic, and 
taurine-treated diabetic. Diabetes was induced in rats by streptozo-
tosin (STZ, single intraperitoneal dose of 50 mg/kg body weight). 
Taurine was administered orally for 12 weeks (1% w/v in drink-
ing water) from the day on which STZ was injected. At the end of 
the 12th week, strips of corpus cavernosum were suspended in an 
organ bath system for functional studies. Nitric oxide (NO)-mediated 
endothelium-dependent and neurogenic corpus cavernosum relaxa-
tion were evaluated by acetylcholine (ACh, 0.1 nM-100 µM) and 
electrical field stimulation (EFS, 30 V, 5 ms, 2–32 Hz), respectively. 
The expressions of endothelial nitric oxide synthase (eNOS), phos-
phorylated eNOS (p-eNOS) (Ser-1177), neuronal nitric oxide syn-
thase (nNOS), NADPH oxidase subunit gp91phox, Rho A, and Rho 
kinase in corpus cavernosum were semi-quantitatively assessed by 
immunohistochemistry.
Results: Induction of diabetes resulted in significant inhibition of 
NO-mediated endothelium-dependent and neurogenic corpus caver-
nosum relaxation. Furthermore, eNOS, p-eNOS, and nNOS expres-
sions decreased significantly in diabetic rats compared with controls, 
while gp91phox, RhoA, and Rho kinase expressions increased signifi-
cantly. The diminished relaxation response to ACh and EFS as well 
as diabetes-related changes in expressions of these proteins in corpus 
cavernosum of diabetic rats were significantly improved by taurine.
Conclusion: Chronic treatment with taurine improves NO-mediated 
relaxations of corpus cavernosum in diabetic rats, probably by inhib-
iting NADPH oxidase/Rho kinase pathways.
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Introduction: Busulfan has documented interindividual phar-
macokinetic variability. Aim of this work is to evaluate acute 
toxicity of parenteral busulfan administered with initial dose 
recommended by producer and to demonstrate the necessity of 
further intensive therapeutic drug monitoring (TDM) to target 
desired exposure.
Patients (or Materials) and Methods: After the provision of an 
informed consent for the procedure per protocol, which has been 
approved by an independent ethical committee, 46 children (male, 
27; median age, 24 months (2 mo–18 years) underwent condition-
ing with parenteral busulfan and other drugs in different combina-
tions for autologous (n = 11) or allogeneic (n = 35) HSCT. Busulfan 
was infused in 42 patients (91%) over 4 days in 16 doses 2 hour 
infusion q6 hourrs with initial dose calculated on body weight (bw; 
< 9 kg 1.0 mg/kg, 9 < 16 kg 1.2 mg/kg, 16–23 kg 1.1 mg/kg, 23 < 34 
kg 0.95 mg/kg, > 34 kg 0.8 mg/kg). In 4 patients (9%), the scheme 
was 4-hour infusion q12 hours for 4 days, starting dose 2 mg/kg bw. 
TDM was performed prospectively online. Samples were collected for 
2-3 days starting 24 hours after initial dose (immediately before, at 
the end, 2 and 4 hours after the end of infusion). Busulfan concentra-
tion was determined by high-performance liquid chromatography. 
Further doses were changed according to calculated AUC (targeted in 
myeloablative range-infusion q6 hours: 5000–7000 ng/m.h, infusion 
q12 hours: 10,000–12,000 ng/mL.h).
